高级搜索
胃肠道间质瘤91例临床分析[J]. 肿瘤防治研究, 2007, 34(01): 59-62. DOI: 10.3971/j.issn.1000-8578.3423
引用本文: 胃肠道间质瘤91例临床分析[J]. 肿瘤防治研究, 2007, 34(01): 59-62. DOI: 10.3971/j.issn.1000-8578.3423
An Analysis of 91 Cases of Gastrointestinal Stromal Tumors[J]. Cancer Research on Prevention and Treatment, 2007, 34(01): 59-62. DOI: 10.3971/j.issn.1000-8578.3423
Citation: An Analysis of 91 Cases of Gastrointestinal Stromal Tumors[J]. Cancer Research on Prevention and Treatment, 2007, 34(01): 59-62. DOI: 10.3971/j.issn.1000-8578.3423

胃肠道间质瘤91例临床分析

An Analysis of 91 Cases of Gastrointestinal Stromal Tumors

  • 摘要: 目的 研究胃肠道间质瘤(GISTs)的临床特点、治疗方法和预后。方法 对1986年-2006年1月在北京协和医院经病理确诊的所有胃肠道间质瘤患者的临床表现、诊断、治疗、预后进行回顾性分析。结果 共有91例确诊的胃肠道间质瘤。主要起源于胃(35例,38.5%)和小肠(30例,33.0%)。68例(75%)有临床症状,最常见临床表现为腹痛、消化道出血、消瘦。内镜和CT对胃肠道间质瘤的诊断比较重要,阳性率超过90%。免疫组化CD117阳性率83.7%,CD34阳性率88.5%。治疗以手术为主,很少发生淋巴转移(3.3%)。7例晚期GISTs行一线化疗,均无效。11例晚期GISTs行伊马替尼治疗,10例可评估,有效率40%,临床获益率80%;中位生存时间已达10个月。91例中84例长期随诊,中位随诊时间13月,中位生存时间16.5月,1年生存率52.9%,2年生存率19.5%。结论 胃肠道间质瘤的临床特点不同于其他常见的消化道肿瘤,CD117对其诊断较为重要,分子靶向治疗延长了晚期GISTs患者的生存。

     

    Abstract: Objective  To study the clinical character, t reatment and prognosis of gast rointestinal stromal tumors. Methods  All cases of gast rointestinal st romal tumors ( GISTs) in PUMCH who were diagnosed between 1986 and J anuary 2006 were analyzed ret rospectively to evaluate their clinical findings. Results  There were totally ninety-one cases. Most of them occured in the stomach (38.5 %) and less commonly in the small intestine (33. 0 %) . 68 cases (75 %) were symptomatic, including abdominal pain, gastroin-testinal bleeding and weight loss. Endoscopy and computed tomograph were two more sensitive way for detection of GISTs. The positive immunohistochemical rate of CD117 and CD34 were 83. 7 % and 88. 5 % respectively in GISTs. The main t reatment of GISTs was surgery. They rarely spread to regional lymph nodes (3. 3 %) . Seven cases of advanced GISTs were t reated with chemotherapy in first line and no case got response. Eleven cases got imatinib. Ten cases could be evaluated. The response rate was 40 %, the disease cont rol rate was 80 % and the median survival time was more than 10 months. Eighty2four cases were long-term followed up and median follow time was 13 months. The median survival time was 16. 5 months, 12year survival rate 52. 9 %, 22year survival rate 19. 5 %. Conclusion  The Clinical characteristics of GISTs are different f rom that of other common gastrointestinal cancers. CD117 is important for the diagnosis of GISTs . Molecular target therapy can improve the survival of the patients with advanced GISTs .

     

/

返回文章
返回